Bachem Hits Fresh Highs as Sales Chief Departs Amid Expansion Drive

Bachem stock surges 8% to new peak despite CCO departure, fueled by strong 2025 results and obesity drug demand. Revenue nears 1 billion franc target.

Bachem shares stormed to a new 52-week peak on Wednesday, climbing 3.2 percent to 77.30 GBP, even as the company announced the departure of its chief commercial officer. The stock later extended gains to trade at 81.10 GBP, marking a gain of roughly eight percent on the session.

The rally underscores investor confidence in the peptide specialist's growth trajectory, which remains undimmed by the sudden exit of Torsten Wöhr. The sales chief is leaving the group in May 2026 to pursue opportunities elsewhere, with CEO Anne-Kathrin Stoller stepping in to handle his responsibilities on an interim basis. A permanent replacement is already being sought.

Wöhr had been instrumental in expanding Bachem's oligonucleotide business while strengthening its position in peptide active ingredients, a segment that has become a cornerstone of modern obesity treatments. The booming demand for weight-loss therapies has been a powerful tailwind for the Swiss group.

The financial results speak for themselves. Bachem posted revenues of 695.1 million Swiss francs for fiscal 2025, an increase of nearly 15 percent year-on-year. Net profit climbed to 148.8 million francs, while EBITDA surged more than 21 percent to 214.7 million francs. The company is now targeting the billion-franc revenue mark by the end of 2026.

To support that ambition, Bachem has been pouring capital into capacity expansion. The new "Building K" production facility in Bubendorf recently came online, designed to meet surging demand for active ingredients used in anti-obesity drugs. A fresh credit line of 500 million francs provides additional financial firepower for strategic growth initiatives.

Shareholders are already seeing the benefits. The dividend for fiscal 2025 was raised to 0.90 francs per share, and analysts expect a further increase to 1.01 francs for 2026. Earnings per share for the current fiscal year are forecast at 2.39 francs.

The stock has gained roughly 20 percent over the past 30 days and is up more than 35 percent since the start of the year. That marks a dramatic recovery from the November low of 48.79 francs. Investors are now looking ahead to the second-quarter results, due at the end of July, for confirmation that the operational momentum remains intact.